Tardive dyskinesia (TD), a neurologic movement disorder, is a distressing and debilitating condition for thousands of patients. The signs and symptoms of TD can appear as those seen in other neurological disorders, including Parkinson’s disease. Despite the hope that the incidence of TD would be declining, data suggest that TD may increase in the coming years. Until now, TD management has been greatly limited by the lack of effective therapies. In 2017, the Food and Drug Administration approved two agents for the treatment of TD in adults.
Case study with interactive benchmarking and video
To enable NPs and PAs to recognize the risk factors and signs of TD in their patients and to counsel them on recently approved treatments for this often debilitating disorder.
After completing this activity, participants should be better able to:
- Identify symptoms of tardive syndromes and TD in order to differentiate them from other extrapyramidal symptoms associated with antipsychotic medications
- Plan strategies for management of tardive syndromes/TD based on current evidence and guidelines
NPs and PAs
CNE Credit Designation Statement
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
Nurse planner: Mary Knudtson, DNSc, NP, University of California, Santa Cruz
AAPA Credit Designation Statement
Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until September 15, 2019. PAs should only claim credit commensurate with the extent of their participation.
This program was planned in accordance with AAPA CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This activity is supported by an educational grant from Neurocrine Biosciences, Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, the AAPA, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are required to disclose to the audience any significant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Kane: advisory board: Alkermes, Intracellular Therapies, Lundbeck, Neurocrine, Otsuka, Pierre Fabre, Takeda, Teva; consultant: Alkermes, Eli Lilly, EnVivo Pharmaceuticals (FORUM), Forest (Allergan), Genentech, Intracellular Therapies, Janssen, Johnson and Johnson, Lundbeck, Merck, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion, Takeda, Teva; grant/research support: Janssen, Lundbeck, Otsuka; shareholder: LB Pharmaceuticals, Vanguard Research Group, Inc.
The Planning Committee for this activity included Ruth Cohen and Jacqueline Egan of Continuing Education Alliance; Mary Knudtson, DNSc, NP, of the University of California, Santa Cruz; and Mark Christiansen, PhD, PA-C, of the University of the Pacific. The members of the Planning Committee have no relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the eCase in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: September 15, 2018
Expiration date: September 15, 2019
© 2018 Practicing Clinicians Exchange. All Rights Reserved. NBPCE94218